ENहिन्दी soon
Home/India/Blog/Who makes Noveltreat, Poviztra and India's other semaglutide brands, and at what MRP?
INIndia Prices

Who makes Noveltreat, Poviztra and India's other semaglutide brands, and at what MRP?

Every semaglutide maker we could confirm, alphabetically: brand, form, strengths, MRP, approval and launch date. No rankings.

GLP Guidebook teamPublished 5 Oct 202612 min read38 sourcesWritten from published sources

Written for India. Reading from the US? US versionComing soon

The short answer

Our table lists 13 companies with semaglutide brands in India, sold as pens, vials or tablets. Generic pens launched at ₹1,800–4,200 for 4 starting doses, and vials from ₹1,290 a month. Poviztra is not a generic; Emcure sells Novo Nordisk's own semaglutide under that name. Yurpeak is tirzepatide, a different medicine.

Key takeaways

  • India's semaglutide brands come from 13 companies in our table, including Sun Pharma (Noveltreat), Emcure (Poviztra) and Dr Reddy's (Obeda), sold as pens, vials or tablets.1,2,3
  • Generic semaglutide pens launched at ₹1,800–4,200 for 4 starting doses, while Natco's and Eris's multi-dose vials start at ₹1,290 a month.3,4,5,6
  • Poviztra is Novo Nordisk's own semaglutide, sold by Emcure as a second brand, at ₹3,999–8,999 a month since 3 April 2026.2
  • Yurpeak injection is Eli Lilly's tirzepatide, not semaglutide, and Cipla sells it at the same price as Mounjaro.7
  • In July 2026, Dr Reddy's and Torrent recalled some batches of generic semaglutide, and USV did too according to industry sources.8
Before you go further
  • GLP‑1 medicines such as semaglutide are prescription-only in India, not sold over the counter.9
  • A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.9,10 CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.11
  • The risks are the same for every brand: Guide 5.
  • Some generic batches were recalled in July 2026 (details below).8
  • This table ranks nothing. No price here recommends a brand or promises a result.
On this page
  1. Who makes semaglutide in India, and in what forms?
  2. Which semaglutide brands are not generics, such as Poviztra?
  3. Is Yurpeak injection a semaglutide generic?
  4. What do semaglutide pens, vials and tablets cost?
  5. What does a CDSCO approval reference tell you?
  6. Which semaglutide batches were recalled in July 2026?
  7. How can you check a semaglutide pen is genuine?
  8. Questions people ask
  9. How we researched this

Who makes semaglutide in India, and in what forms?

Our table lists 13 companies in alphabetical order. Three sell semaglutide made by Novo Nordisk; ten sell their own version or a partner's.2,12,13

Alphabetical order is not a ranking. MRP means maximum retail price, the price printed on the pack. Each row gives form, strengths and MRP as the maker or a named report gave it. Where a maker gave a weekly price, we show it as weekly.

Some companies sell another company's product. Eris sells semaglutide made by Natco, and Lupin co-markets Zydus's version under its own brand names.14,15

Company and brandsForm and strengthsMRP (source, date)Approval and launch
AbbottExtensiorMade by Novo Nordisk Pen; 0.25, 0.5 and 1 mg16 ₹3,999 / ₹4,999 / ₹5,999 per pen16Pharmacy-listed MRP, 2+ listings agree, 5 Oct 2026. Abbott published no price. Type 2 diabetes; a second brand of Ozempic12Announced 27 Feb 2026
AlkemSemasize, Obesema, Hepaglide Disposable pen of 4 doses; reusable pen for higher doses40.25, 0.5, 1, 1.7 and 2.4 mg for weight17 From ₹1,800 a month (disposable pen)4Maker, 21 Mar 2026. Other strengths: not published. Type 2 diabetes and weight, after Phase 3 trials in India (DCGI)4; CDSCO committee, 9 Dec 202517Launched 21 Mar 2026
Dr Reddy'sObeda Disposable pen, at least 4 weekly doses; 2 mg and 4 mg pens3 ₹4,200 a month, both strengths3Company, via Business Standard, 21 Mar 2026 Type 2 diabetes; CDSCO committee, 11 Sep 202518Launched 21 Mar 2026Some batches recalled, Jul 2026
EmcurePoviztraMade by Novo Nordisk Pen; 0.25, 0.5, 1, 1.7 and 2.4 mg19 ₹3,999 (0.25 mg), ₹4,999 (0.5 mg), ₹5,999 (1 mg), ₹7,999 (1.7 mg), ₹8,999 (2.4 mg) a month19Indian Pharma Post, 2 Apr 2026; effective 3 Apr 2026 Weight management; a second brand of Novo's semaglutide2Launched Dec 202520
ErisSundae Multi-dose vials, 2 mg/1.5 mL and 4 mg/3 mL; pens announced for April 20266 Vials from ₹1,290 a month6,13Pens announced at ₹4,000 / ₹4,200 / ₹4,500 a month (2, 4, 8 mg), 21 Mar 2026 Approved use not stated by Eris. Made by Natco, whose own approval is for type 2 diabetes5,14Launched Mar 202613
GlenmarkGLIPIQ Vial (with dose-specific syringes) and pen; 2 mg/1.5 mL, 4 mg/3 mL, 8 mg/3 mL21 Vials ₹325–440 a week21Maker, 21 Mar 2026. Pen: not published. Type 2 diabetes; CDSCO approval after a Phase III study in India21Launched 21 Mar 2026
LupinSemanext, Livarise Zydus's reusable pen, 15 mg/3 mL cartridge15,22 Not published Zydus's product15Deal announced 17 Mar 202615. Launch not confirmed
NatcoSemanat, Semafull Multi-dose vials, 2 mg/1.5 mL, 4 mg/3 mL, 8 mg/3 mL; pens announced for April 20265 Vials ₹1,290 a month (2 and 4 mg), ₹1,750 (8 mg)5Company, via Business Standard, 20 Mar 2026. Pens announced at ₹4,000 / ₹4,200 / ₹4,500. Type 2 diabetes23; CDSCO approval Feb 2026, after a clinical comparison study5Launched 20 Mar 2026
Novo NordiskOzempic, Wegovy, Rybelsus Ozempic pen 0.25, 0.5, 1 mg; Wegovy pen, 5 strengths24,25; Rybelsus tablets (our Answer) Ozempic ₹5,660–9,100; Wegovy ₹5,660–16,400 a month25Business Standard, from 1 Apr 2026 Ozempic: type 2 diabetes; heart and kidney use, CDSCO committee, 17 Jul 202526Wegovy Jun 202527; Ozempic Dec 202524
Sun PharmaNoveltreat; Sematrinity Noveltreat: pre-filled pen, 0.25, 0.5, 1, 1.7, 2.4 mg. Sematrinity: multi-dose pen, 2 mg/1.5 mL, 4 mg/3 mL1 Noveltreat ₹900–2,000 a week; Sematrinity ₹750–1,300 a week1Maker, 21 Mar 2026 Noveltreat: weight. Sematrinity: type 2 diabetes. DCGI, Dec 2025 and Jan 202628; CDSCO committee, 9 Dec 202517Launched 21 Mar 2026
TorrentSemalix, Sembolic Semalix pens 2, 4 and 8 mg; Sembolic reusable pen; tablets of both brands, 3, 7 and 14 mg29 Injection from ₹3,999 a month30Maker, 21 Mar 2026. Tablets: not published. Pens made by Dr Reddy's (2, 4 mg), MSN (8 mg) and Zydus (Sembolic)29Launched 21 Mar 202630Some 2 mg and 4 mg pen batches recalled, Jul 2026
USVUsema Pens, 2 mg and 4 mg; 8 mg "shortly"31 Not published Type 2 diabetes; DCGI-approved; launched in collaboration with Dr Reddy's31Launched 21 Mar 2026Batches recalled, per industry sources
ZydusSemaglyn, Mashema, Alterme Reusable multi-dose pen with a 15 mg/3 mL cartridge; one pen gives different dose strengths32 About ₹2,200 a month, on average32Company, 21 Mar 2026 Type 2 diabetes and weight; CDSCO committee, 9 Dec 202517Launched 21 Mar 2026

Alphabetical by company, not ranked. MRPs come from makers or named, dated news reports. "Pharmacy-listed" means the printed MRP on at least 2 pharmacy listings that agree, never a discounted price. Checked 5 Oct 2026; prices may have changed since launch.

Not in the table. Mankind Pharma said before the expiry that it would launch a brand called Samakind.14 We found no maker statement or report with its form or price, so we left it out.

A pre-launch list in March named 55 brands.33 A name on a list like that doesn't prove the product is on sale. By July, Medical Dialogues counted more than 50 CDSCO-approved generic products on the market.8

Which semaglutide brands are not generics, such as Poviztra?

Poviztra and Extensior are second brands of Novo Nordisk's own semaglutide. Indian partners sell them, and Novo Nordisk makes them.2,12

Poviztra. Emcure "exclusively distributes and commercializes" it in India as a second brand of Novo Nordisk's semaglutide.2 It launched in December 2025 at ₹8,790 a month for the starting dose.20 From 3 April 2026 it costs ₹3,999 (0.25 mg) to ₹8,999 (2.4 mg) a month.2

Emcure's chief executive called it "the innovator molecule, not a biosimilar or generic".20 For the brand Novo sells itself, see Wegovy vs Ozempic.

Searching "Poviztra" often brings up Brazilian pages. Novo Nordisk uses the same name in Brazil, where the leaflet is headed as the Wegovy leaflet.34 Approvals and packs in Brazil can differ from India's.

Extensior. Abbott sells it as "a second brand of Ozempic", for type 2 diabetes. It is "developed and manufactured by Novo Nordisk".12

Two ways to make the same medicine. CDSCO describes Novo's Wegovy pens as semaglutide of "r-DNA origin".35 The expert-committee minutes for the generics we checked say "synthetic origin".17,18 We found no public CDSCO comparison of the two.

Is Yurpeak injection a semaglutide generic?

No. Yurpeak is tirzepatide, the medicine in Mounjaro. Eli Lilly makes it, and Cipla sells it as Lilly's second tirzepatide brand in India.7

Cipla launched Yurpeak on 10 December 2025, for type 2 diabetes and weight management. It comes as a KwikPen in 6 strengths, from 2.5 mg to 15 mg.7

Cipla said "the price will be the same as Mounjaro".7 Pharmacy listings print an MRP of ₹13,125 for the 2.5 mg pen and ₹25,781 for 15 mg.36 Our short answers explain what tirzepatide is and whether Mounjaro is available in India.

What do semaglutide pens, vials and tablets cost?

Generic pens launched at ₹1,800–4,200 for 4 starting doses. Vials are priced per vial, from ₹1,290 a month.3,4,5

  • Pens, starting doses: ₹1,800–4,200 for 4 doses at launch.3,4
  • Pens, top doses, where published: ₹4,200–8,000 for 4 doses. One maker prices its top dose by the week, at ₹2,000 (₹8,000 for 4 doses).1,3
  • Vials: from ₹1,290 a month, and ₹1,750 for an 8 mg vial. One maker gives ₹325–440 a week.5,6,21
  • Novo-made pens: Ozempic ₹5,660–9,100, Wegovy ₹5,660–16,400 and Poviztra ₹3,999–8,999 a month.2,25

We keep vials apart from pens because makers price them per vial, by month or week, not per dose. With a vial, you draw each dose with a syringe; Glenmark supplies dose-specific syringes.21 Guide 6 explains why measuring doses needs care.

Tablets. Torrent sells generic semaglutide tablets in 3, 7 and 14 mg.29 We found no published price. Novo's tablet is Rybelsus.

A worked example. We count a year as 52 weekly doses, so a month is about 4.3 doses. A pen of 4 doses at ₹4,200 needs 13 pens a year: 13 × ₹4,200 = ₹54,600.3

Most of these are launch prices from March 2026. In July, Medical Dialogues put generic therapy at "around Rs 1,290 to Rs 8,000" a month.8

Free toolWork out the 6- and 12-month cost

Medicine MRP, doctor visits and tests, by dose step. No sign-up.

Open the calculator

What does a CDSCO approval reference tell you?

It shows what each brand was approved for. Every maker needs its own approval, and approved uses differ from brand to brand.17,18

CDSCO's expert committee (the Subject Expert Committee) reviews each maker's trial data. It then recommends whether to let the company "manufacture and market" the medicine.18

  • 11 Sep 2025: the committee accepted Dr Reddy's Phase III report. It recommended approval for type 2 diabetes, at 2, 4 and 8 mg.18
  • 9 Dec 2025: it recommended Sun Pharma's and Alkem's versions for weight management. Zydus's was recommended for weight and type 2 diabetes.17
  • Each of those weight approvals came with a condition: a post-marketing safety study in India.17

So a brand approved only for type 2 diabetes, such as Obeda or Sematrinity, does not carry a weight-management approval.1,3 Some companies say their approval followed a Phase 3 trial in India, including Alkem, Sun Pharma and Glenmark.4,21,28

One minutes file has no date in its name and may be reused. So we also cite archived copies. Our short answer Is semaglutide the same as Ozempic? explains medicine versus brand.

Which semaglutide batches were recalled in July 2026?

In July 2026, Dr Reddy's and Torrent recalled some batches of generic semaglutide, and USV did too according to industry sources. These were selected batches, not whole brands.8,29

The table flags the three brands affected. Torrent said its tablets, its 8 mg pen and the Sembolic reusable pen were not part of the recall.29 Our post on what changed when semaglutide went generic has the full account.

If you have one of these brands, don't just stop. Find the batch number on the pack and ask the pharmacy or the company about it.29 Tell your doctor before any change of brand. Guide 6 also covers recalls.

How can you check a semaglutide pen is genuine?

Start with where it came from: a licensed pharmacy, against your prescription, with a bill. Then check the packaging, expiry date and that it was kept cold.35,37

In August 2025, CDSCO warned that Novo Nordisk stock was stolen in transit. It included Wegovy pens of batches RP5S232 (0.25 mg), RP5S233 (0.5 mg) and RP5S210 (1 mg).35 CDSCO told patients to buy "from authorized sources only and with proper invoice".35

The same alert said these medicines must be stored at 2–8°C, or their quality may be compromised.35 The WHO warns that fake semaglutide may contain another medicine, such as insulin.37 It advises checking packaging and expiry dates.37

Our full checklist is in Fake Ozempic and Mounjaro pens: how do you check yours in India?

RisksThe risks, in brief: the same for every brand
  • Stomach effects are common. In the Wegovy 2.4 mg trials, 44% felt sick (nausea), against 16% on a dummy injection.38
  • Pancreatitis (an inflamed pancreas) has been seen with these medicines, including severe cases.38
  • Gallbladder problems, such as gallstones.38
  • Dehydration from vomiting or diarrhoea can hurt the kidneys.38
  • Thyroid warning: ruled out by the US label for people with a personal or family history of MTC or MEN 2; tell your doctor if this applies. Not in pregnancy: stop at least 2 months before a planned pregnancy.38
Full detail in Guide 5: Side effects and risks →
Get help now: call 112 for severe stomach pain that won't go away, with or without vomiting. It can be pancreatitis.38

Questions people ask

What is Poviztra?

Poviztra is Novo Nordisk's semaglutide, sold in India by Emcure as a second brand for weight management. Since 3 April 2026 it costs ₹3,999–8,999 a month.2

Is Yurpeak injection the same as semaglutide?

No. Yurpeak is tirzepatide, made by Eli Lilly and sold by Cipla. Cipla said its price would be the same as Mounjaro's.7

Who makes Noveltreat?

Sun Pharma. It launched Noveltreat on 21 March 2026 for chronic weight management, in 5 strengths, at about ₹900–2,000 a week.1

Which semaglutide generic is the best or cheapest?

We don't rank brands. They differ in approved use, form and strength, and prices change after launch. A doctor chooses the brand and dose.8,17

Do generic semaglutide brands need a prescription?

Yes. The government said on 1 April 2026 that GLP-1 medicines cannot be bought over the counter.9

How we researched this

We opened every company release, news report, CDSCO file and pharmacy listing below on 5 October 2026. MRPs follow our order: maker first, then a named, dated news report. Next comes NPPA, then a printed MRP on 2 or more agreeing pharmacy listings. We found no NPPA price for semaglutide.

We could not confirm a launch price for Lupin, USV, Glenmark's pen or any generic tablet. We could not confirm that Natco's and Eris's pens launched in April. We left out pre-launch brand lists and aggregator sites.

The risk figures come from the US Wegovy label, not the Indian one. We could not find the Indian label online.

Before you move on

  • Brands differ in form, strengths and approved use, so a diabetes-only brand is not a weight brand.
  • Poviztra and Extensior are Novo-made; Yurpeak is tirzepatide.
  • Compare pens with pens. Vials are priced per vial.
  • Some generic batches were recalled in July 2026; check yours with the pharmacy.
Side effects and risksI have type 2 diabetesCost calculator

More from the India blog

INIndiaWhat changed for Ozempic when semaglutide's patent expired in India? INIndiaWegovy vs Ozempic: same medicine, different brand? INIndiaFake Ozempic and Mounjaro pens: how do you check yours in India?
About GLP Guidebook

The monthly India update

An independent guide to GLP‑1 medicines. We don't sell medicines, take drug-company money or earn clinic commissions. Once a month: new brands, price changes, approvals and recalls. How we write

Was this post easy to understand?

Sources

  1. Sun Pharmaceutical Industries. Sun Pharma launches its semaglutide injection under the brand names Noveltreat and Sematrinity in India. Press release, 21 March 2026. PDF
  2. Medical Dialogues (Parthika Patel). Emcure Pharma cuts Poviztra price by 55%, starting dose now Rs 3,999 per month. 4 April 2026. Link
  3. Business Standard (Capital Market). Dr Reddy's launches Obeda (semaglutide) in India for Type 2 Diabetes. 21 March 2026. Link
  4. Alkem Laboratories. Alkem Laboratories launches semaglutide injection in India at weekly therapy cost starting INR 450. Press release, 21 March 2026. PDF
  5. Business Standard (Capital Market). Natco Pharma gains after launching generic diabetes drug semaglutide. 20 March 2026. Link
  6. BioSpectrum India. Eris Lifesciences introduces weekly shot of semaglutide starting at Rs 220 per shot. 21 March 2026. Link
  7. Cipla. Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes. Press release, 10 December 2025. PDF
  8. Medical Dialogues (Farhat Nasim). Recalls by Dr Reddy's, Torrent put spotlight on quality standards in India's semaglutide market. 10 July 2026. Link
  9. Outlook India (PTI). Inspections, surveillance to continue against unauthorised sale, promotion of GLP-1 weight-loss drugs: Govt. 1 April 2026. Link
  10. PIB Research (Government of India). GLP-1 drugs: use, risks, and regulation. 1 April 2026. PDF
  11. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 13–14 February 2024. Items 3–4, semaglutide (Novo Nordisk): warning statement "To be sold by retail on the prescription of an Endocrinologist, and Internal medicine". PDF · Archived copy
  12. Abbott India. Abbott partners with Novo Nordisk India to launch Extensior, broadening access to semaglutide (Ozempic) for advanced diabetes management. Press release, 27 February 2026. Link
  13. Reuters (Rishika Sadam). Factbox: Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy. 23 March 2026 (via Stockopedia). Link
  14. BusinessToday (Neetu Chandra Sharma). Pharma firms opt for partnerships as India's semaglutide market opens post patent expiry. 19 March 2026. Link
  15. Lupin. Lupin and Zydus sign licensing agreement for co-marketing innovative semaglutide injection in India. Press release, 17 March 2026. Link
  16. Extensior MRP per pen: 0.25 mg ₹3,999 (Apollo Pharmacy, PharmEasy and Tata 1mg listings), 0.5 mg ₹4,999 (Apollo Pharmacy and Tata 1mg), 1 mg ₹5,999 (Apollo Pharmacy, Tata 1mg and Truemeds). MrMed and SastaSundar still list higher MRPs (₹8,400–10,600). Pharmacy-listed printed MRP, checked 5 October 2026. Cited as plain text, not linked.
  17. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 25th/25 meeting, 9 December 2025. Items 4–7: semaglutide for chronic weight management (Sun Pharmaceutical Industries; Alkem Laboratories; Zydus Lifesciences) and type 2 diabetes (Zydus Lifesciences). PDF · Archived copy
  18. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 19th/25 meeting, 11 September 2025. Semaglutide injection 2 mg, 4 mg and 8 mg (Dr Reddy's Laboratories), type 2 diabetes. PDF · Archived copy
  19. Indian Pharma Post (IPP Bureau). Emcure Pharma reduces Poviztra starting dose price by 55% in India (revised monthly MRPs, inclusive of taxes, effective 3 April 2026). 2 April 2026. Link
  20. Business Standard (Anjali Singh). Emcure targets pan-India obesity market with Poviztra semaglutide. 22 December 2025. Link
  21. Glenmark Pharmaceuticals. Glenmark Pharmaceuticals launches GLIPIQ (semaglutide) in India. Press release, 21 March 2026. PDF
  22. Zydus Lifesciences. Zydus plans to launch innovative semaglutide injection in India on Day 1 of patent expiry. Press release, 25 February 2026. PDF
  23. BusinessToday (Neetu Chandra Sharma). NATCO opens semaglutide market at ₹1,290, sets early price benchmark. 20 March 2026. Link
  24. Business Standard (Sarjna Rai). Novo Nordisk launches Ozempic in India at ₹2,200/week amid patent battles. 12 December 2025. Link
  25. Business Standard. As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices. 31 March 2026. Link
  26. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 15th/25 meeting, 17 July 2025. Item 3, semaglutide injection 0.25, 0.5 and 1 mg (Novo Nordisk): additional heart and kidney indication in type 2 diabetes. PDF (file name without a date) · Archived copy
  27. BusinessToday. India's weight loss drug moment: what happens when semaglutide goes generic. 20 March 2026. Link
  28. Sun Pharmaceutical Industries. Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management. Press release, 23 January 2026. PDF
  29. Medical Dialogues Health (Bhumika Maikhuri). Torrent Pharma recalls select Semalix injection batches after Dr Reddy's flags quality issue. 10 July 2026. Link
  30. Torrent Pharmaceuticals. Torrent Pharma launches oral and injectable formulations of semaglutide. Press release, 21 March 2026. PDF
  31. BioSpectrum India. USV launches "usema" to address India's metabolic health burden. 21 March 2026. Link
  32. BioSpectrum India. Zydus launches semaglutide injection in reusable multi-dose pen device in India. 21 March 2026. Link
  33. Medical Dialogues (Farhat Nasim). India's semaglutide market set for generic boom as patents expire, over 50 brands lined up for launch. 4 March 2026. Link
  34. Novo Nordisk Brazil. Poviztra (semaglutida) patient leaflet, headed "Bula Wegovy 04/05/2026" (Brazilian leaflet, not Indian). PDF
  35. CDSCO, Enforcement & Intelligence Cell. Alert on theft of multiple drug products of M/s Novo Nordisk during transit. F. No. Enforc-11021(11)/46/2025-eoffice, 21 August 2025. PDF · archived copy
  36. Yurpeak KwikPen MRP: 2.5 mg ₹13,125 (Apollo Pharmacy and PharmEasy listings), 15 mg ₹25,781 (Tata 1mg ₹25,781.25 and PharmEasy). Pharmacy-listed printed MRP, checked 5 October 2026. Cited as plain text, not linked.
  37. World Health Organization. WHO issues warning on falsified medicines used for diabetes treatment and weight loss. 20 June 2024. Link
  38. Novo Nordisk. Wegovy (semaglutide) prescribing information, revised June 2026 (US label, not the Indian one): boxed warning, sections 5.2–5.5 and 8.3, Table 3, and patient counselling (17). PDF

Last checked 5 Oct 2026 · Next review due 5 Apr 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write